These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
580 related items for PubMed ID: 14993882
1. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Chiorean EG, DeFor TE, Weisdorf DJ, Blazar BR, McGlave PB, Burns LJ, Brown C, Miller JS. Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882 [Abstract] [Full Text] [Related]
7. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S, Yabe H, Kato S, Imoto S, Maruta A, Yoshida T, Gondo H, Morishima Y, Kodera Y. Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659 [Abstract] [Full Text] [Related]
10. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175 [Abstract] [Full Text] [Related]
12. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia. Gardiner N, Lawler M, O'Riordan JM, Duggan C, De Arce M, McCann SR. Bone Marrow Transplant; 1998 Apr; 21(7):711-9. PubMed ID: 9578312 [Abstract] [Full Text] [Related]
15. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732 [Abstract] [Full Text] [Related]
16. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Carlens S, Remberger M, Aschan J, Ringdén O. Biol Blood Marrow Transplant; 2001 Dec; 7(1):31-8. PubMed ID: 11215696 [Abstract] [Full Text] [Related]